参考文献/References:
[1] Zhou Y,U X.Demographic characteristics and illegal drug use patterns among attendees of drug cessation programs in China.Subst Use Misuse,1999,34(6):907-920.
[2] Noble F,Sziics M,Kieffer B,et al.Overexpression of dynamin is induced by chronic stimulation of mu-but not delta-opioid receptors:relationships with mu-related morphine dependence.Mol Pharma-col,2000,58(1):159-166.
[3] Matthes HW,Maldonado R,Simonin F,et al.Loss of morphine-induced analgesia,reward effect and withdrawal symptoms in micelacking the mu-opioid-receptor gene.Nature,1996,383(6603):819-823.
[4] Sante AB,Nobre MJ,Brandão ML.Place aversion induced by blockade of mu or activation of kappa opioid receptors in the dorsal periaqueductal gray matter.Behav Pharmacol,2000,11(7-8):583-589.
[5] Dannals RF,Ravert HT,Frost JJ,et al.Radiosynthesis of an opiatereceptor binding radiotracer:[11C] carfentanil.Int J Appl RadiatIsot,1985,36(4):303-306.
[6] Weerts EM,Wand GS,Kuwabara H,et al.Positron emission tomog-raphy imaging of mu-and delta-opioid receptor binding in alcohol-dependent and healthy control subjects.Alcohol Cli Exp Res,2011,35(12):2162-2173.
[7] Tuominen L,Salo J,Hirvonen J,et al.Temperament trait HarmAvoidance associates with)X-opioid receptor availability in frontalcortex:a PET study using[11C] carfentanil.Neuroimage,2012,61(3):670-676.
[8] Zubieta J,Greenwald MK,Lombardi U,et al.Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers:a preliminary study.Neuropsychopharma-cology,2000,23(3):326-334.
[9] Smith JS,Zubieta JK,Price JC,et al.QuantiHcation of delta-opioid receptors in human brain with Nl’-([11C] methyl) naltrindole and positron emission tomography,J Cerebr Blood Flow Metab,1999,19(9):956-966.
[10] Frost JJ,Mayberg HS,Sadzot B,et al.Comparison of [11C] diprenor-phine and[11C] carfentanil binding to opiate receptors in humans bypositron emission tomography.J Cerebr Blood Flow Metab,1990,10(4):484-492.
[11] Galynker I,Schlyer DJ,Dewey SL,et al.Opioid receptor imagingand displacement studies with[6-0-[11C] methyl] buprenorphine inbaboon brain.Nucl Med Biol,1996,23(3):325-331.
[12] 王荣福,何晓坤,张春丽,等.一种新的阿片受体显像剂125I-7α-0-碘烷-特培洛菲的制备及生物学评价.中华医学杂志,2004,84(5):420-422.
[13] David V,Cazala P.Anatomical and pharmacological specificity of the rewarding effect elicited by microinjections of morphine into the nucleus accumbens of mice.Psychopharmacology (Berl),2000,150(1):24-34.
[14] Schoffelmeer AN,Wardeh G,Vanderschuren LJ-Morphine acutely and persistently attenuates nonvesicular GABA release in rat nucle-us accumbens.Synapse,2001,42(2):87-94.
[15] Hnasko TS,Sotak BN,Palmiter RD.Morphine reward in dopamine-deficient mice.Nature,2005,438(7069):854-857.
[16] Nanni C,Fanti S,Rubello D.18F-DOPA PET and PET/CT.J Nucl Med,2007,48(10):1577-1579.
[17] Dackis CA,Gold MS.New concepts in cocaine addiction:the dopamine depletion hypothesis.Neurosci Biobehav Rev,1985,9(3):469-477.
[18] Kiyatkin EA,Rebec GV.Impulse activity of ventral tegmental area neurons during heroin self-administration in rats.Neuroscience,2001,102(3):565-580.
[19] Chartoff EH,Mague SD,Barhight MF,et al.Behavioral and molec-ular effects of dopamine D1 receptor stimulation during naloxone-precipitated morphine withdrawal.J Neurosci,2006,26(24):6450-6457.
[20] Le Foil B,Francès H,Diaz J,et al.Role of the dopamine D3 recep-tor in reactivity to cocaine-associated cues in mice.Eur J Neurosci,2002,15(12):2016-2026.
[21] Li T,Hou Y,Cao W,et al.Role of dopamine D3 receptors in basal nociception regulation and in morphine-induced tolerance and withdrawal.Brain Res,2012,1433:80-84.
[22] Sershen H,Hashim A,Lajtha A.Differences between nicotine and cocaine-induced conditioned place preferences.Brain Res Bull,2010,81(1):120-124.
[23] Laihinen AO,Rinne JO,Ruottinen HM,et al.PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756.J Nucl Med,1994,35(12):1916-1920.
[24] Wagner H N Jr,Bums H D,Dannals RF,et al.Imaging dopaminereceptors in the human brain by positron tomography.Science,1983,221(4617):1264-1266.
[25] Urban NB,Slifstein M,Thompson JL,et al.Dopamine release in chronic cannabis users:a[11C] raclopride positron emission tomog-raphy study.Biol Psychiatry,2012,71(8):677-683.
[26] Martinez D,Saccone PA,Liu F,et al.Deficits in dopamine D(2) receptors and presynaptic dopamine in heroin dependence:com-monalities and differences with other types of addiction.Biol Psy-chiatry,2012,71(3):192-198.
[27] Searle G,Beaver JD,Comley R A,et al.Imaging dopamine D3 receptors in the human brain with positron emission tomography,[11C] PHNO,and a selective D3 receptor antagonist.Biol Psychiatry,2010,68(4):392-399.
[28] Spielewoy C,Gonon F,Roubert C,et al.Increased rewarding prop-erties of morphine in dopamine-transporter knockout mice.Eur J Neurosci,2000,12(5):1827-1837.
[29] 贾少微,时杰,欧阳钢,等.应用单光子发射计算机体层摄影术研究药物滥用对人脑纹状体多巴胺转运体的损害.中华精神科杂志,2005,38(2):69-72.
[30] Cosgrove KP,Tellez-Jacques K,Pittman B,et al.Dopamine and serotonin transporter availability in chronic heroin users:a[123I]β-CIT SPECT imaging study.Psychiatry Res,2010,184(3):192-195.
[31] Shi J,Zhao LY,Copersino ML,et al.PET imaging of dopamine transporter and drug craving during methadone maintenance treat-ment and after prolonged abstinence in heroin users.Eur J Pharma-col,2008,579(1-3):160-166.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[5]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[6]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[7]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[8]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[9]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[10]程维维,王辉.促甲状腺激素受体与甲状腺癌关系的研究进展[J].国际放射医学核医学杂志,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
CHENG Wei-wei,WANG Hui.Progress in the relationship of thyroid-stimulating hormone receptor and thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]